{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["51(3)"],"submitter":["Madurka I"],"funding":["Novartis Pharma AG"],"pubmed_abstract":["<h4>Background</h4>Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm.<h4>Methods</h4>This randomised, multinational study enrolled hospitalised patients (18-80 years) with COVID-19-associated pneumonia and impaired respiratory function. Eligible patients were randomised (1:1) via Interactive Response Technology to DFV890 + standard-of-care (SoC) or SoC alone for 14 days. Primary endpoint was APACHE II score at Day 14 or on day-of-discharge (whichever-came-first) with worst-case imputation for death. Other key assessments included clinical status, CRP levels, SARS-CoV-2 detection, other inflammatory markers, in-hospital outcomes, and safety.<h"],"journal":["Infection"],"pagination":["641-654"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9473473"],"repository":["biostudies-literature"],"pubmed_title":["DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function."],"pmcid":["PMC9473473"],"pubmed_authors":["Zerega N","Bhan S","Goebeler ME","Datta A","Kurguzova D","Pabel S","Iharos D","Viladomiu AS","Malacize VQ","Bauernfeind S","Lazarenko IV","Kotov ME","Sag S","Flores EMZ","Ulrik CS","Egorova EA","Junge G","Orihuela BG","Perez ROF","Ore DJS","Welte T","Alferov SP","Marcos MC","Bachman M","Esze T","Olzik I","Frey A","Pedersen KBH","Blinova EV","Rodriguez BNL","Martynenko TI","Hejja M","Moncivais BS","Kharlamova S","Schulze P","Mc Harry K","Hanses F","Meiser K","Sementsov KV","Brigante JA","Osornio JS","Pink I","Scharf N","Krishnamurthy S","Gounder SKM","Hakansson K","Barbosa GR","Zeller J","Medina MAJ","Del Pino RM","Ganova OS","Radchenko EN","Toth KK","Kaneesan K","Weismann D","McHarry K","Paraeva OS","Serrano DR","Bagu AM","Stoll M","Ripfel S","Soriano JB","Nalin S","Saha A","Vishneva EM","Sayehli CM","Mohan A","Kist GR","Rudikh OV","Fernandes CC","Rendon A","Hinovker VV","Gatalsky KK","Cardozo C","Vaidyanathan V","Agrawal A","Unnithan MRJ","Belekhov GA","Farronay MIM","Boeve-Epping N","Katagarov DN","Filik H","Repnikov I","Stadnik CMB","Gans SJ","Gatlik E","Bhopale S","Leisner U","Shearman N","Mehes B","Boom L","Bustios ERM","Pandit A","Geismann F","VanDen Berg JW","Vishnevsky A","Messnikov O","Jaoude CVG","Klinker H","Singh R","Martynov AV","Antonov VN","Krylov AA","Pinzhina VN","Panhuis E","Vishnevsky AY","Tiwari P","Trufanov KV","Soriano J","Gaygolnik TV","Ignatova GL","Costa MB","Lammens M","Bondareva YA","Ratre BK","Ramos EA","Ortiz AC","Morozov E","Garcia F","Benfield T","Madurka I","Sommer U","Lancee G","Pashkevich VV","Garkavi DA","Study group","Abramov VG","Kiseleva M","Grebneva IV","Lubnow M","Rezende E","Vig S","Srikanth A","de Olivera EP","Vergara AM","Hupf J","Smolyarchuk EA","de Carvalho Rezende EA","Ortega MLM","Velayuthaswamy N","Rodionova OV","Fernandez AA","Ragognete HG","Srinivasan N","Ahmed NJ","Bacci MR","Tidemandsen C","Vasileva E","Hitzenbichler F","Perez DLC","Amido FH","Bhatnagar S","Bhattacharjee A","Maier L","Ramirez EJR","Terskikh MM","Snyman E","Franco G","Isakova AP","Budhraja A","Zykov VA","Kumar B"],"additional_accession":[]},"is_claimable":false,"name":"DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.","description":"<h4>Background</h4>Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm.<h4>Methods</h4>This randomised, multinational study enrolled hospitalised patients (18-80 years) with COVID-19-associated pneumonia and impaired respiratory function. Eligible patients were randomised (1:1) via Interactive Response Technology to DFV890 + standard-of-care (SoC) or SoC alone for 14 days. Primary endpoint was APACHE II score at Day 14 or on day-of-discharge (whichever-came-first) with worst-case imputation for death. Other key assessments included clinical status, CRP levels, SARS-CoV-2 detection, other inflammatory markers, in-hospital outcomes, and safety.<h","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-06-18T07:00:44.471Z","creation":"2024-12-03T16:19:55.011Z"},"accession":"S-EPMC9473473","cross_references":{"pubmed":["36104613"],"doi":["10.1007/s15010-022-01904-w"]}}